¼¼°è ¹ÙÀÌ¿À¹öµç ½ÃÇè ½ÃÀå : Á¦Ç° À¯Çüº°, °Ë»ç À¯Çüº°, ¿ëµµº°, ÃÖÁ¾ »ç¿ëÀÚº°, ±¹°¡º°, Áö¿ªº° »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2024³â-2032³â)
Bioburden Testing Market, By Product Type, By Test Type, By Application, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
»óǰÄÚµå : 1462938
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2024³â 04¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 368 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,502,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,441,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 7,826,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¹ÙÀÌ¿À¹öµç ½ÃÇè ½ÃÀå ±Ô¸ð´Â 2023³â 12¾ï 1,023¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í 2024³âºÎÅÍ 2032³â±îÁö º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 11.5%·Î È®´ëµÉ Àü¸ÁÀÔ´Ï´Ù.

¹ÙÀÌ¿À¹öµç ½ÃÇè ½ÃÀå - ½ÃÀå ¿ªÇÐ

°í±Þ ½¬ÇÁÅÍ ½Ã½ºÅÛÀÇ µîÀåÀ¸·Î ½ÃÀå ¼ö¿ä ÃËÁø

½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀ¸·Î´Â ¹Ì»ý¹° ¿À¿°¿¡ ÀÇÇÑ Á¦Ç° ȸ¼öÀÇ ºó¹ß, »ý¸í °úÇÐ ºÐ¾ß¿¡¼­ÀÇ R&D ÅõÀÚ Áõ°¡ µîÀÌ ÀÖ½À´Ï´Ù. ÀǾàǰ ¹× »ý¹°Á¦Á¦ÀÇ Á¦Á¶ °úÁ¤¿¡¼­ ¹Ì»ý¹° ¿À¿°°ú »ý¹° ºÎÇÏÀÇ À§ÇèÀÌ ³ô¾ÆÁö´Â °ÍÀº Á¦Ç° ¸®ÄÝ µîÀÇ ÀáÀçÀûÀÎ ¿µÇâÀ» °í·ÁÇÏ¿© Á¤ºÎ³ª ±â¾÷ü¿¡ À־ ´Ù¾çÇÑ »ý¹°ÇÐÀû ¾ÈÀü ´ëÃ¥À» ½Ç½ÃÇÏ´Â Áß¿äÇÑ Àμ¾Æ¼ºê¿Í µÇ¾î ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 6¿ù, Green Pharmaceuticals Inc.´Â Providencia rettgeri¿¡ ÀÇÇÑ ¹Ì»ý¹° ¿À¿°À¸·Î ÀÎÇØ SnoreStop NasoSpray lot 2373/2122¸¦ ÀÚ¹ßÀûÀ¸·Î ȸ¼öÇß½À´Ï´Ù. ¸¶Âù°¡Áö·Î 2022³â 3¿ùPlastikon Healthcare, LLC´Â ¹Ì»ý¹° ¿À¿°°ú ¹Ì»ý¹° °Ë»ç ½ÇÆÐÀÇ ºÎÀûÀýÇÑ °Ë»ç¸¦ À§ÇØ °æ±¸ ÇöŹ¾× Á¦Ç°À» ¸®ÄÝÇß½À´Ï´Ù.

¹ÙÀÌ¿À¹öµç ½ÃÇè ½ÃÀå - ÁÖ¿ä ÀλçÀÌÆ®·Â

¿ì¸®ÀÇ ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®°¡ °øÀ¯ÇÑ ºÐ¼®¿¡ µû¸£¸é ½ÃÀåÀº ¿¹Ãø ±â°£(2024³â-2032³â)¿¡ ¾à 11.5%ÀÇ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Á¦Ç° À¯Çüº°·Î ¼Ò¸ðǰÀº 2023³â ÃÖ´ë ½ÃÀå Á¡À¯À²À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÃÖÁ¾ »ç¿ëÀÚº°·Î´Â 2023³â¿¡´Â Á¦Á¶ ¼öʱâ°üÀÌ ÁÖ¿ä À¯ÇüÀ̾ú½À´Ï´Ù.

Áö¿ªº°·Î ºÏ¹Ì´Â 2023³â ÁÖ¿ä ¼öÀÍ¿øÀÌ µÇ¾ú½À´Ï´Ù.

¹ÙÀÌ¿À¹öµç ½ÃÇè ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼® :

¹ÙÀÌ¿À¹öµç ½ÃÇè ½ÃÀåÀº Á¦Ç° À¯Çü, °Ë»ç À¯Çü, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚ, Áö¿ª¿¡ µû¶ó ¼¼ºÐÈ­µË´Ï´Ù.

½ÃÀåÀº Á¦Ç° À¯Çü¿¡ µû¶ó ¼Ò¸ðǰ°ú ÀåºñÀÇ µÎ °¡Áö·Î ³ª´¹´Ï´Ù. 2023³â¿¡´Â ¼Ò¸ðǰ ºÎ¹®ÀÌ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ÀÌÁ¡Àº ÁÖ·Î ÀÏȸ¼º ÅõÀÚ·Î °£ÁֵǴ Àåºñ¿Í ´Þ¸® ŰƮ ¹× ½Ã¾àÀ» ¹Ýº¹ÀûÀ¸·Î ±¸ÀÔÇÏ´Â Áö¼ÓÀûÀÎ ¿ä±¸ »çÇ× ¶§¹®ÀÔ´Ï´Ù.

½ÃÀåÀº ÃÖÁ¾ »ç¿ëÀÚº°·Î Á¦¾à,¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷, ÀÇ·á±â±â Á¦Á¶¾÷ü, ÀǾàǰ Á¦Á¶ ¼öʱâ°ü(CMO), À½½Ä½Äǰ Á¦Á¶¾÷ü, ³ó»ê¹° Á¦Á¶¾÷ü, ¹Ì»ý¹° °Ë»ç½ÇÀÇ 5°³·Î ºÐ·ùµË´Ï´Ù. 2023³â ¿¹Ãø±â°£¿¡¼­´Â ÀǾàǰ Á¦Á¶ ¼öʱâ°ü(CMO) ºÐ¾ß°¡ °¡Àå ³ôÀº º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¼ºÀåÀº Á¦¾à ȸ»ç ¹× »ý¸í °øÇРȸ»ç¿¡¼­ ÀǾàǰ Á¦Á¶ ¼öŹ ±â°üÀ¸·ÎÀÇ Á¦Á¶ °øÁ¤ÀÇ ¾Æ¿ô¼Ò½Ì µ¿Çâ Áõ°¡°¡ ¹è°æ¿¡ ÀÖ½À´Ï´Ù.

¹ÙÀÌ¿À¹öµç ½ÃÇè ½ÃÀå - Áö¸®Àû ÀλçÀÌÆ®

ÀÌ ½ÃÀåÀº ºÏ¹Ì, ¶óƾ¾Æ¸Þ¸®Ä«, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç ¹× Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«¿¡ ³Î¸® ºÐÆ÷µÇ¾î ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀº ºñÁî´Ï½º¸¦ Á¦°øÇÏ´Â ±¹°¡¿¡ ÀÇÇØ ´õ ³ª´¹´Ï´Ù.

¹ÙÀÌ¿À¹öµç ½ÃÇè ½ÃÀå - °æÀï ±¸µµ:

¹ÙÀÌ¿À¹öµç ½ÃÇè ½ÃÀå¿¡¼­ ±â¾÷Àº Àü·«Àû ÆÄÆ®³Ê½ÊÀ» Ȱ¿ëÇÏ¿© ÀÚÁÖ ´É·ÂÀ» °­È­ÇÏ°í ½ÃÀå µµ´Þ¹üÀ§¸¦ È®´ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÆÄÆ®³Ê½Ê¿¡´Â Á¾Á¾ °Ë»ç ´É·ÂÀ» °­È­ÇÏ°í ¼ö¿ä º¯µ¿¿¡ ´ëÀÀÇϱâ À§ÇØ °Ë»ç À§Å¹ ±â°ü°úÀÇ Á¦ÈÞ°¡ Æ÷ÇԵ˴ϴÙ. ¶ÇÇÑ, ±ÔÁ¦ Àü¹®°¡¿ÍÀÇ Á¦ÈÞ´Â ÁøÈ­ÇÏ´Â ±âÁذú Áöħ¿¡ ´ëÇÑ ÄÄÇöóÀ̾𽺸¦ º¸ÀåÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ±â¼ú °ø±ÞÀÚ¿ÍÀÇ Á¦È޴ ÷´Ü °Ë»ç ¹æ¹ýÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí Á¤È®¼º°ú È¿À²¼ºÀ» Çâ»ó½Ãŵ´Ï´Ù. Àü·«Àû ÆÄÆ®³Ê½ÊÀ» ÅëÇØ ±â¾÷Àº ¹ÙÀÌ¿À¹öµç ½ÃÇè ½ÃÀåÀÇ ÁöÀ§¸¦ ³ôÀÌ°í °í°´ÀÇ ¿ä±¸¿¡ ´õ Àß ´ëÀÀÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¹ÙÀÌ¿À¹öµç ½ÃÇè ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¹ÙÀÌ¿À¹öµç ½ÃÇèÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå ¹ÙÀÌ¿À¹öµç ½ÃÇè ¾÷°èÀÇ ¿¬±¸

Á¦5Àå ¹ÙÀÌ¿À¹öµç ½ÃÇè ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå ¹ÙÀÌ¿À¹öµç ½ÃÇè ½ÃÀå »óȲ

Á¦7Àå ¹ÙÀÌ¿À¹öµç ½ÃÇè ½ÃÀå-Á¦Ç° À¯Çüº°

Á¦8Àå ¹ÙÀÌ¿À¹öµç ½ÃÇè ½ÃÀå - ½ÃÇè À¯Çüº°

Á¦9Àå ¹ÙÀÌ¿À¹öµç ½ÃÇè ½ÃÀå- ¿ëµµº°

Á¦10Àå ¹ÙÀÌ¿À¹öµç ½ÃÇè ½ÃÀå - ÃÖÁ¾ »ç¿ëÀÚº°

Á¦11Àå ¹ÙÀÌ¿À¹öµç ½ÃÇè ½ÃÀå-Áö¿ª

Á¦12Àå ÁÖ¿ä º¥´õ ºÐ¼® - ¹ÙÀÌ¿À¹öµç ½ÃÇè ¾÷°è

Á¦13Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

BJH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Bioburden Testing Market size was valued at USD 1,210.23 Million in 2023, expanding at a CAGR of 11.5% from 2024 to 2032.

Bioburden testing plays a pivotal role in the pharmaceutical and medical device sectors, serving to quantify the presence of viable microorganisms on or within a product. This process is essential for ensuring product safety and efficacy, as it assesses microbial contamination levels and verifies compliance with regulatory standards.

Bioburden Testing Market- Market Dynamics

Advent of the advanced shifter system to propel market demand

The primary drivers of market growth include the frequent occurrence of product recalls due to microbial contamination and rising investments in research and development within the life sciences sector. The heightened risk of microbial contamination and bioburden during pharmaceutical and biologics manufacturing serves as a significant incentive for governments and corporate entities to implement diverse biological safety practices, given the potential repercussions such as product recalls. For example, in June 2022, Green Pharmaceuticals Inc voluntarily recalled lot 2373/21222 of SnoreStop NasoSpray due to microbiological contamination with Providencia rettgeri. Similarly, in March 2022, Plastikon Healthcare, LLC recalled several lots of oral suspension products due to microbial contamination and inadequate examination of failed microbiological testing.

Bioburden Testing Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 11.5% over the forecast period (2024-2032)

Based on product type segmentation, consumables was predicted to show maximum market share in the year 2023

Based on end user segmentation, contract manufacturing organizations was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Bioburden Testing Market- Segmentation Analysis:

The Global Bioburden Testing Market is segmented on the basis of Product Type, Test Type, Application, End User, and Region.

The market is divided into two categories based on product type: consumables and instruments. In 2023, the consumables segment is projected to hold the largest market share. This dominance is primarily attributed to the ongoing requirement for repeat purchases of kits and reagents, unlike instruments which are considered a one-time investment.

The market is divided into five categories based on end user: pharmaceutical and biotechnology companies, medical device manufacturers, contract manufacturing organizations (CMOs), manufacturers of food and beverage, agricultural product manufacturers, and microbial testing laboratories. In 2023, the contract manufacturing organizations (CMOs) segment is expected to exhibit the highest compound annual growth rate (CAGR) during the forecast period. This growth is driven by the increasing trend of outsourcing manufacturing processes from pharmaceutical and biotechnology companies to contract manufacturing organizations.

Bioburden Testing Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

Bioburden Testing Market- Competitive Landscape:

In the bioburden testing market, companies frequently leverage strategic partnerships to bolster their capabilities and expand their market reach. These partnerships often involve collaborations with contract testing laboratories to increase testing capacities and accommodate fluctuations in demand. Additionally, alliances with regulatory experts aid in ensuring compliance with evolving standards and guidelines. Collaborations with technology providers facilitate the adoption of advanced testing methods, leading to improvements in accuracy and efficiency. Through strategic partnerships, companies can enhance their position in the bioburden testing market and better cater to the needs of their clientele.

Recent Developments:

In August 2022, Lonza introduced the Nebula Multimode Reader, marking the first multimode reader certified for use with Lonza's turbidimetric, chromogenic, and recombinant endotoxin detection methodologies. Furthermore, in April 2023, STEMart, a U.S.-based provider of comprehensive services for all stages of medical device development, launched Bioburden and Sterility Testing services for medical devices, guided by the ISO 11731 method.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BIOBURDEN TESTING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHT

Eissmann Group Automotive

Orscheln Products

Dura

Kongsberg Automotive

M&T Allied Technologies

ZF

Delta Kogyo

Kostal

Stoneridge

Fuji Kiko

Silatech Srl

GHSP

Kuster

Ficosa

Atsumitec

Others

GLOBAL BIOBURDEN TESTING MARKET, BY PRODUCT TYPE - MARKET ANALYSIS, 2019 - 2032

GLOBAL BIOBURDEN TESTING MARKET, BY TEST TYPE- MARKET ANALYSIS, 2019 - 2032

GLOBAL BIOBURDEN TESTING MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

GLOBAL BIOBURDEN TESTING MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

GLOBAL BIOBURDEN TESTING MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1.Bioburden Testing Market Overview

2.Executive Summary

3.Bioburden Testing Key Market Trends

4.Bioburden Testing Industry Study

5.Bioburden Testing Market: COVID-19 Impact Analysis

6.Bioburden Testing Market Landscape

7.Bioburden Testing Market - By Product Type

8.Bioburden Testing Market - By Test Type

9.Bioburden Testing Market - By Application

10.Bioburden Testing Market - By End User

11.Bioburden Testing Market- By Geography

12.Key Vendor Analysis- Bioburden Testing Industry

13.360 Degree Analyst View

14.Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â